Double‐blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants

Double‐blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants

See also Furberg CD, Soliman EZ. Double-blindness protects scientific validity. This issue, pp 230-1; Casteels M, Flamion B. Open-label trials and drug registration: a European regulator's view. This issue, pp 232-4.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and haemostasis 2008-02, Vol.6 (2), p.227-229
Hauptverfasser: BÜLLER, H. R., HALPERIN, J. L., BOUNAMEAUX, H., PRINS, M.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:See also Furberg CD, Soliman EZ. Double-blindness protects scientific validity. This issue, pp 230-1; Casteels M, Flamion B. Open-label trials and drug registration: a European regulator's view. This issue, pp 232-4.
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/j.1538-7836.2008.02848.x